Disappointing topline results from high dose biotin study
A large clinical trial evaluating high dose biotin (MD1003, Qizenday) in secondary and primary progressive MS has failed to show that the treatment leads to improvements in disability.
Topline results from the study have been announced in a press release from the manufacturer, MedDay. Detailed results of the study will be presented at the American Academy of Neurology (AAN) meeting in Toronto, April 2020.
About the study
The SPI2 trial evaluated the safety and effectiveness of three daily doses of 100mg of high dose biotin compared to placebo in 642 people with progressive MS without recent relapses, also called non-active progressive MS. The main measure of the study was an improvement in disability, which could be either a lower EDSS score or a reduction in the time to walk 25 feet. There was no improvement in either of these measures in comparison to the placebo group.
About MD1003
MD1003 is a highly concentrated formulation of biotin which has been undergoing clinical studies.
An earlier clinical trial (MS-SPI) which recruited 154 participants with progressive MS had provided initial evidence that high doses of biotin might have an impact on disability and progression. The main measure of the study was improvement in disability after 9 months of treatment which was still evident at 12 months. Improvement in disability could be either a reduction in EDSS or a reduction in the time to walk 25 feet. Slightly less than 13% of the MD1003 group and none of the placebo group met this criteria.
Biotin, also known as vitamin H or coenzyme R, is one of the B-group vitamins (vitamin B7). It is involved in a wide range of cell processes. It has been suggested that very high doses of biotin may be effective in MS by promoting myelin repair through activation of an enzyme involved in myelin synthesis and by enhancing energy production in demyelinated nerves.
Find out more


Updated NICE multiple sclerosis guideline contains some good news and some bad news
22/06/2022 - 00:00
There are some positive points in the revised 2022 guideline but the MS Trust is disappointed that NICE has been unable to recommend Fampyra.


The ADAMS project
25/05/2022 - 00:00
Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.


Is a ketogenic diet good for people with multiple sclerosis?
18/05/2022 - 00:00
Researchers assessed whether a ketogenic diet, low in carbohydrates and high in fats, is suitable for people with multiple sclerosis.


Updated NICE multiple sclerosis guideline contains some good news and some bad news
22/06/2022 - 00:00
There are some positive points in the revised 2022 guideline but the MS Trust is disappointed that NICE has been unable to recommend Fampyra.


Connors letter to MS
21/06/2022 - 00:00
In 2022, Connor will be taking part in the Great North Run to support the MS Trust. Here, Connor writes a letter to MS, openly sharing his thoughts on the condition his sister was diagnosed with at the age of 14.


Why is Pride month important to the MS Trust?
16/06/2022 - 00:00
As part of our Pride month celebrations, two of the MS Trust team who identify as members of the LGBTQ+ community, sat down with David Martin, the MS Trust’s CEO, to discuss the importance of celebrating the LGBTQ+ community - not just in June but throughout the year.

Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.